Korean Circ J.  2024 Aug;54(8):497-498. 10.4070/kcj.2024.0209.

Brightening Your Vision With Fractional Flow Reserve and Intravascular Ultrasound

• Cha JJ
• Hong SJ

• KMID: 2558541
• DOI: http://doi.org/10.4070/kcj.2024.0209

Reference

1. Hannan EL, Zhong Y, Reddy P, et al. Percutaneous coronary intervention with and without intravascular ultrasound for patients with complex lesions: utilization, mortality, and target vessel revascularization. Circ Cardiovasc Interv. 2022; 15:e011687. PMID: 35543139.

2. Parikh RV, Liu G, Plomondon ME, et al. Utilization and outcomes of measuring fractional flow reserve in patients with stable ischemic heart disease. J Am Coll Cardiol. 2020; 75:409–419. PMID: 32000953.

3. Ahn SG, Lee SJ. Dose coronary angiography suffice for assessment of intermediate coronary stenosis? Korean Circ J. 2019; 49:1033–1034. PMID: 31456370.

4. De Bruyne B, Fearon WF, Pijls NH, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014; 371:1208–1217. PMID: 25176289.

5. Elgendy IY, Mahmoud AN, Elgendy AY, Bavry AA. Outcomes with intravascular ultrasound-guided stent implantation: a meta-analysis of randomized trials in the era of drug-eluting stents. Circ Cardiovasc Interv. 2016; 9:e003700. PMID: 26980883.

6. Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv. 2019; 12:e007023. PMID: 31345066.

7. Cha JJ, Kim D, Kim BK, et al. Association between angiographic and intravascular ultrasound optimizations after new-generation drug-eluting stent implantation and clinical outcomes. Coron Artery Dis. 2021; 32:541–548. PMID: 33471477.

8. Lee JH, Ahn SG, Jeon HS, et al. Discordance between angiographic assessment and fractional flow reserve or intravascular ultrasound in intermediate coronary lesions: a post-hoc analysis of the FLAVOUR trial. Korean Circ J. 2024; 54:485–496. PMID: 38956940.

9. Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024; 403:1753–1765. PMID: 38604213.

10. Yang S, Koo BK. Coronary physiology-based approaches for plaque vulnerability: implications for risk prediction and treatment strategies. Korean Circ J. 2023; 53:581–593. PMID: 37653694.